The CFO's share sale was made under a pre-set plan and is not a bearish signal
The CFO's share sale was made under a pre-set plan and is not a bearish signal. The sell side has no consensus on how to value peptides, so the real re-rating window is the 11 May earnings report and the 23 Jul FDA advisory committee. After a 48% gain in a week, the narrative has moved from GLP-1 risk to peptide opportunity, and chasing the move in the short term calls for caution.
Analyst views
- BofA
Raised its target from $21 to $25 (peptides a positive), then cut it back to $21 (worried that a GLP-1 revenue decline of about 50% will weigh on EBITDA)
- Consensus
The average target price of 17 analysts is $31.71 and the shares have already touched $31, so the consensus target is largely priced in
- Key uncertainty
The sell side has no consensus at all on how to value peptides
- Leerink
Maintained its $25 target: peptides will not turn into revenue in the short term, but their strategic value is clear
CFO insider sale
- Conclusion
A routine plan sale, not a bearish signal
- Plan
All sales were made under a Rule 10b5-1 plan adopted on 21 May 2025, so they were not reactive
- Remaining holdings
288,051 shares held directly, 7,853 shares in trust and 129,403 unexercised options
- Summary
CFO Oluyemi Okupe sold 54,927 shares (about $1.46 million) on 16-17 Apr and exercised options over 6,184 shares (exercise price $5.01)
Price action
- Media
Heavy coverage in mainstream media such as Forbes
- Move
Up 48% in a week, surging from the $21 range to $31
- Narrative shift
From 'GLP-1 risk stock' to 'peptide opportunity and platform re-rating'
Risk flag
The short-term gain is huge and the stock is in overbought territory, so a pullback is a real possibility. Medium-term catalysts are clear, but chasing the move in the short term calls for caution.
Catalysts to watch
- 11 May Q1 earnings: management sets out its peptide strategy
- Outcome of the FDA advisory committee on 23-24 Jul
A brief is a lead for our research, not a verified conclusion or advice.